Monopar Therapeutics
MNPR
56 hedge funds and large institutions have $354M invested in Monopar Therapeutics in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
213% more capital invested
Capital invested by funds: $113M → $354M (+$241M)
30% more funds holding
Funds holding: 43 → 56 (+13)
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
18.33% more ownership
Funds ownership: 51.94% → 70.28% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.3M |
| 2 |
DM
Deerfield Management
New York
|
+$7.14M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$6.95M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$6.84M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.72M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$621K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$535K |
| 4 |
Millennium Management
New York
|
-$333K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$223K |
MNPR Hedge Fund Activity: Q3 2025 in Review
56 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2025, worth a combined $354M — up 213% from $113M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MNPR positions and 3 closed out — a net gain of 13 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $10.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.72M sold.
- 56 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2025, up from 43 in Q2 2025.
- Funds reported $354M of Monopar Therapeutics stock for Q3 2025, up 213% quarter-over-quarter.
- 16 funds opened new Monopar Therapeutics positions in Q3 2025 and 3 closed out, a net change of +13 holders.
- The largest Monopar Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $10.3M added.
- The largest Monopar Therapeutics seller in Q3 2025 was Point72 Asset Management, an estimated $3.72M sold.
Based on aggregated 13F filings for Q3 2025.